• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中心性浆液性脉络膜视网膜病变的影像生物标志物

Central serous chorioretinopathy imaging biomarkers.

作者信息

Singh Sumit Randhir, Iovino Claudio, Zur Dinah, Masarwa Dua, Iglicki Matias, Gujar Ramkailash, Lupidi Marco, Maltsev Dmitrii S, Bousquet Elodie, Bencheqroun Mehdi, Amoroso Francesca, Lima Luiz H, Padhy Srikanta Kumar, Govindahari Vishal, Chandra Khushboo, Souied Eric H, Rodriguez Francisco J, Daza Laura A, Rios Hernan A, Cagini Carlo, Peiretti Enrico, Behar-Cohen Francine, Chhablani Jay

机构信息

Jacobs Retina Center, University of California San Diego, La Jolla, California, USA.

Eye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences, Università degli studi della Campania "Luigi Vanvitelli", Naples, Italy.

出版信息

Br J Ophthalmol. 2022 Apr;106(4):553-558. doi: 10.1136/bjophthalmol-2020-317422. Epub 2020 Dec 7.

DOI:10.1136/bjophthalmol-2020-317422
PMID:33288526
Abstract

PURPOSE

To identify the factors predicting the visual and anatomical outcomes in eyes with central serous chorioretinopathy (CSCR) through 12 months.

METHODS

Patients with diagnosis of CSCR, either acute or chronic, were included in this multicentric, retrospective study. Demographic factors; systemic risk factors; central macular thickness (CMT), subfoveal choroidal thickness (SFCT), linear extent of ellipsoid zone (EZ) and interdigitation zone damage on optical coherence tomography; details of leak on fluorescein angiography and indocyanine green angiography were included as predictors of anatomical and visual outcomes. Regression analysis was performed to correlate the changes in best corrected visual acuity (BCVA) and resolution of disease activity.

RESULTS

A total of 231 eyes of 201 patients with a mean age (49.7±11.8 years) were analysed. A total of 97 and 134 eyes were classified as acute and chronic CSCR. BCVA (0.35±0.31 to 0.24±0.34; p<0.001), baseline optical coherence tomography (OCT) parameters including CMT (p<0.001), subretinal fluid (SRF) height (p<0.001) and SFCT (p=0.05) showed a significant change through 12 months. Multivariate regression analysis showed change in CMT (p≤0.01) and SRF height at baseline (p=0.05) as factors predictive of good visual outcome. Logistic regression analysis revealed changes in both CMT (p=0.009) and SFCT (p=0.01) through 12 months to correlate with the resolution of disease.

CONCLUSION

OCT parameters such as changes in both CMT and SFCT along with subfoveal EZ damage can be predictive of disease resolution whereas changes in CMT and baseline SRF height correlate well with changes in BCVA through 12 months.

摘要

目的

确定预测中心性浆液性脉络膜视网膜病变(CSCR)患者12个月时视力及解剖学转归的因素。

方法

本多中心回顾性研究纳入急性或慢性CSCR诊断患者。人口统计学因素、全身危险因素、光学相干断层扫描(OCT)测量的中心黄斑厚度(CMT)、黄斑中心凹下脉络膜厚度(SFCT)、椭圆体带(EZ)线性范围及指状交叉区损伤;荧光素血管造影和吲哚菁绿血管造影渗漏细节作为解剖学和视力转归的预测指标。进行回归分析以关联最佳矫正视力(BCVA)变化和疾病活动度消退情况。

结果

共分析201例患者的231只眼,平均年龄(49.7±11.8岁)。97只眼和134只眼分别分类为急性和慢性CSCR。BCVA(从0.35±0.31至0.24±0.34;p<0.001)、包括CMT(p<0.001)、视网膜下液(SRF)高度(p<0.001)和SFCT(p=0.05)在内的基线OCT参数在12个月时显示出显著变化。多因素回归分析显示CMT变化(p≤0.01)和基线SRF高度(p=0.05)是良好视力转归的预测因素。逻辑回归分析显示12个月期间CMT(p=0.009)和SFCT(p=0.01)的变化与疾病消退相关。

结论

OCT参数如CMT和SFCT变化以及黄斑中心凹下EZ损伤可预测疾病消退,而CMT变化和基线SRF高度与12个月期间BCVA变化密切相关。

相似文献

1
Central serous chorioretinopathy imaging biomarkers.中心性浆液性脉络膜视网膜病变的影像生物标志物
Br J Ophthalmol. 2022 Apr;106(4):553-558. doi: 10.1136/bjophthalmol-2020-317422. Epub 2020 Dec 7.
2
Identifying central serous chorioretinopathy biomarkers in coexisting diabetic retinopathy: a multimodal imaging study.在并存的糖尿病性视网膜病变中鉴定中心性浆液性脉络膜视网膜病变的生物标志物:一项多模态成像研究。
Br J Ophthalmol. 2020 Jul;104(7):904-909. doi: 10.1136/bjophthalmol-2019-314077. Epub 2019 Sep 28.
3
OCT biomarkers related to subthreshold micropulse laser treatment effect in central serous chorioretinopathy.与中心性浆液性脉络膜视网膜病变阈下微脉冲激光治疗效果相关的 OCT 生物标志物。
BMC Ophthalmol. 2022 Jun 7;22(1):252. doi: 10.1186/s12886-022-02472-1.
4
Intravitreal Brolucizumab for Chronic Central Serous Chorioretinopathy without Choroidal Neovascular Membrane - a Pilot Study.玻璃体内布罗鲁单抗治疗无脉络膜新生血管膜的慢性中心性浆液性脉络膜视网膜病变 - 一项初步研究。
Semin Ophthalmol. 2024 Nov;39(8):615-622. doi: 10.1080/08820538.2024.2308808. Epub 2024 Jan 25.
5
One year outcome and predictors of treatment outcome in central serous chorioretinopathy: Multimodal imaging based analysis.中心性浆液性脉络膜视网膜病变的一年结局及治疗结局预测因素:基于多模态成像的分析
Eur J Ophthalmol. 2022 Jul;32(4):2319-2327. doi: 10.1177/11206721211055018. Epub 2021 Nov 6.
6
[Observation on long-term efficacy of half-dose photodynamic therapy with chronic central serous chorioretinopathy using optical coherence tomography].[应用光学相干断层扫描观察半剂量光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变的长期疗效]
Zhonghua Yan Ke Za Zhi. 2016 May;52(5):328-34. doi: 10.3760/cma.j.issn.0412-4081.2016.05.004.
7
The effect of nondamaging subthreshold laser therapy in patients with chronic central serous chorioretinopathy.非损伤性亚阈值激光疗法对慢性中心性浆液性脉络膜视网膜病变患者的疗效。
Graefes Arch Clin Exp Ophthalmol. 2024 May;262(5):1433-1442. doi: 10.1007/s00417-023-06315-7. Epub 2023 Nov 27.
8
Therapeutic Efficacy of Spironolactone for Central Serous Chorioretinopathy.螺内酯治疗中心性浆液性脉络膜视网膜病变的疗效。
Yonsei Med J. 2022 Apr;63(4):365-371. doi: 10.3349/ymj.2022.63.4.365.
9
Spironolactone versus observation in the treatment of acute central serous chorioretinopathy.螺内酯治疗与观察治疗急性中心性浆液性脉络膜视网膜病变的疗效比较。
Br J Ophthalmol. 2018 Aug;102(8):1060-1065. doi: 10.1136/bjophthalmol-2017-311096. Epub 2017 Oct 31.
10
Choroidal Anatomic Alterations After Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: A Multicenter Study.慢性中心性浆液性脉络膜视网膜病变光动力疗法后脉络膜解剖结构的改变:一项多中心研究。
Am J Ophthalmol. 2020 Sep;217:104-113. doi: 10.1016/j.ajo.2020.04.022. Epub 2020 Apr 28.

引用本文的文献

1
Pigment epithelium detachment with thickened choroid in a preterm infant at term-equivalent age: a case report.足月小样儿色素上皮脱离伴脉络膜增厚:1例报告
Front Med (Lausanne). 2025 Aug 12;12:1581191. doi: 10.3389/fmed.2025.1581191. eCollection 2025.
2
Choroidal vessel changes in acute and chronic central serous chorioretinopathy assessed by en-face Layer-by-Layer comparison and correlation.通过逐层对比和相关性分析评估急性和慢性中心性浆液性脉络膜视网膜病变中的脉络膜血管变化。
Sci Rep. 2025 Apr 28;15(1):14894. doi: 10.1038/s41598-025-98576-x.
3
Fluorescein angiography patterns and subretinal hyperreflective material predict subthreshold micropulse laser response in chronic central serous chorioretinopathy.
荧光素血管造影模式和视网膜下高反射物质预测慢性中心性浆液性脉络膜视网膜病变中阈下微脉冲激光的反应。
BMC Ophthalmol. 2024 Nov 4;24(1):478. doi: 10.1186/s12886-024-03711-3.
4
New high-resolution prototype versus standard spectralis optical coherence tomography in patients with central serous chorioretinopathy.新型高分辨率原型与标准Spectralis光学相干断层扫描技术在中心性浆液性脉络膜视网膜病变患者中的应用比较
Int J Retina Vitreous. 2024 Oct 16;10(1):78. doi: 10.1186/s40942-024-00598-6.
5
Importance of OCT-derived biomarkers for the recurrence of central serous chorioretinopathy using statistics and predictive modelling.利用统计学和预测模型评估 OCT 衍生生物标志物在中心性浆液性脉络膜视网膜病变复发中的重要性。
Sci Rep. 2024 Oct 13;14(1):23940. doi: 10.1038/s41598-024-75275-7.
6
Analysis of optical coherence tomography biomarker probability detection in central serous chorioretinopathy by using an artificial intelligence-based biomarker detector.使用基于人工智能的生物标志物检测器分析中心性浆液性脉络膜视网膜病变中光学相干断层扫描生物标志物的概率检测
Int J Retina Vitreous. 2024 May 31;10(1):42. doi: 10.1186/s40942-024-00560-6.
7
Efficacy and Predictive Factors of Oral Spironolactone Treatment in Chronic Central Serous Chorioretinopathy.口服螺内酯治疗慢性中心性浆液性脉络膜视网膜病变的疗效及预测因素
J Ophthalmol. 2024 Mar 18;2024:7197249. doi: 10.1155/2024/7197249. eCollection 2024.
8
Half-dose photodynamic therapy versus 577 nm subthreshold pulse laser therapy in treatment-naive patients with central serous chorioretinopathy.半剂量光动力疗法与 577nm 亚阈脉冲激光治疗初治中心性浆液性脉络膜视网膜病变的比较。
BMC Ophthalmol. 2024 Jan 4;24(1):8. doi: 10.1186/s12886-023-03274-9.
9
Photoreceptor outer segment layer thinning as a biomarker in acute central serous chorioretinopathy.急性中心性浆液性脉络膜视网膜病变中光感受器外节层变薄作为一种生物标志物
Ther Adv Ophthalmol. 2023 Mar 21;15:25158414231160689. doi: 10.1177/25158414231160689. eCollection 2023 Jan-Dec.
10
Intralenticular Ozurdex injection in an eye with thicker lens and the therapeutic effect maintained for 15 months.在晶状体较厚的眼睛中进行玻璃体内Ozurdex注射,治疗效果维持了15个月。
Heliyon. 2022 Dec 9;8(12):e12219. doi: 10.1016/j.heliyon.2022.e12219. eCollection 2022 Dec.